The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Abstract
Summary: Dabigatran etexilate is an oral, reversible direct thrombin inhibitor that is approved in the EU and several other countries for the prevention of venous thromboembolism after elective hip and knee replacement, and is in advanced clinical development for other thromboembolic disorders. Dabigatran has a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for routine coagulation monitoring. In certain clinical situations such as serious bleeding into critical organs (e.g. intracerebral bleeding), potential overdose and emergency surgery, clinicians will need to make an assessment of the anticoagulant status of a patient receiving dabigatran before deciding on future management strategies. If available, thrombin clotting time (TT), ecarin clotting time (ECT) and TT determined by Hemoclot→ thrombin inhibitor assay are sensitive tests to evaluate the anticoagulant effects of dabigatran. Prothrombin time (INR) is less sensitive than other assays and cannot be recommended. The activated partial thromboplastin time (aPTT) can provide a useful qualitative assessment of anticoagulant activity but is less sensitive at supratherapeutic dabigatran levels. There are limited data for activated clotting time (ACT). Overall, the aPTT and TT are the most accessible qualitative methods for determining the presence or absence of anticoagulant effect. Although there is no specific antidote to antagonise the anticoagulant effect of dabigatran, due to its short duration of effect drug discontinuation is usually sufficient to reverse any excessive anticoagulant activity. In case of potential overdose, the feasibility of early administration of activated charcoal and subsequent charcoal filtration are undergoing preclinical evaluation. Dabigatran can also be dialysed in patients with renal impairment. In instances of life-threatening bleeding, where conventional measures have failed or are unavailable, other non-specific prohaemo -static agents such as recombinant activated factor VII and prothrombin complex concentrates can be considered. Disclosure statement: All authors are employees of Boehringer Ingelheim. Figure 1 has been corrected in this version of the article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes
Eikelboom, J. W., Mehta, S. R., Anand, S. S., Xie, C., Fox, K. A. A., & Yusuf, S. (2006) · Circulation · doi:10.1161/circulationaha.106.612812 · Cited by 1,341
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Self-citationManoukian, S. V., Feit, F., Mehran, R., Voeltz, M. D., Ebrahimi, R., Hamon, M., Dangas, G. D., Lincoff, A. M., White, H. D., Moses, J. W., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.027 · Cited by 798
Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., & Weitz, J. I. (2008) · Chest · doi:10.1378/chest.08-0689 · Cited by 755
Stangier, J., Rathgen, K., Stähle, H., & Mazur, D. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318170-000000000-00000 · Cited by 722
Self-citationThe Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689
Self-citationStangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655
Self-citation
Cited by
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552
Self-citationAgeno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Horlocker, T. T., Wedel, D. J., Rowlingson, J. C., Enneking, F. K., Kopp, S. L., Benzon, H. T., Brown, D. L., Heit, J. A., Mulroy, M. F., Rosenquist, R. W., et al. (2010) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0b013e3181c15c70 · Cited by 1,501
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Antithrombotic Therapy for Atrial Fibrillation
Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M., Werring, D., et al. (2018) · Chest · doi:10.1016/j.chest.2018.07.040 · Cited by 939
Horlocker, T. T., Vandermeuelen, E., Kopp, S. L., Gogarten, W., Leffert, L. R., & Benzon, H. T. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000763 · Cited by 932
Antithrombotic Therapy for Atrial Fibrillation
You, J. J., Singer, D. E., Howard, P. A., Lane, D. A., Eckman, M. H., Fang, M. C., Hylek, E. M., Schulman, S., Go, A. S., Hughes, M., et al. (2012) · Chest · doi:10.1378/chest.11-2304 · Cited by 918
Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology
Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P., Santullano, C. A. A., De Robertis, E., Filipescu, D. C., Fries, D., Görlinger, K., Haas, T., Imberger, G., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 909
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · Europace · doi:10.1093/europace/eut083 · Cited by 792
A specific antidote for dabigatran: functional and structural characterization
Schiele, F., van Ryn, J., Canada, K., Newsome, C., Sepulveda, E., Park, J., Nar, H., & Litzenburger, T. (2013) · Blood · doi:10.1182/blood-2012-11-468207 · Cited by 563
Healey, J. S., Eikelboom, J., Douketis, J., Wallentin, L., Oldgren, J., Yang, S., Themeles, E., Heidbuchel, H., Avezum, A., Reilly, P., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.090464 · Cited by 541
Marlu, R., Hodaj, E., Paris, A., Albaladejo, P., Crackowski, J., & Pernod, G. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-03-0179 · Cited by 501
Diener, H.-C., Connolly, S. J., Ezekowitz, M. D., Wallentin, L., Reilly, P. A., Yang, S., Xavier, D., Di Pasquale, G., & Yusuf, S. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70274-x · Cited by 451
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
Cuker, A., Siegal, D. M., Crowther, M. A., & Garcia, D. A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.065 · Cited by 449
Siegal, D., Yudin, J., Kaatz, S., Douketis, J. D., Lim, W., & Spyropoulos, A. C. (2012) · Circulation · doi:10.1161/circulationaha.112.105221 · Cited by 440
Mekaj, A., Mekaj, Y., Duci, S., & Miftari, E. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s84210 · Cited by 407
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht134 · Cited by 405
Tomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Gluckman, T. J., Hucker, W. J., Mehran, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.053 · Cited by 397
Gosselin, R., Adcock, D., Bates, S., Douxfils, J., Favaloro, E., Gouin-Thibault, I., Guillermo, C., Kawai, Y., Lindhoff-Last, E., & Kitchen, S. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1627480 · Cited by 392
Levy, J. H., Ageno, W., Chan, N. C., Crowther, M., Verhamme, P., & Weitz, J. I. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13227 · Cited by 375
How I treat anticoagulated patients undergoing an elective procedure or surgery
Spyropoulos, A. C., & Douketis, J. D. (2012) · Blood · doi:10.1182/blood-2012-06-415943 · Cited by 375
Lakkireddy, D., Reddy, Y. M., Di Biase, L., Vanga, S. R., Santangeli, P., Swarup, V., Pimentel, R., Mansour, M. C., D'Avila, A., Sanchez, J. E., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.014 · Cited by 356
Wang, Z., Frost, C., Shenker, A., & Barrett, Y. C. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-05-0328 · Cited by 356
Dabigatran Etexilate: A New Oral Thrombin Inhibitor
Hankey, G. J., & Eikelboom, J. W. (2011) · Circulation · doi:10.1161/circulationaha.110.004424 · Cited by 348
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants
Samuelson, B. T., Cuker, A., Siegal, D. M., Crowther, M., & Garcia, D. A. (2017) · Chest · doi:10.1016/j.chest.2016.08.1462 · Cited by 345
Tomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Hucker, W., Mehran, R., Messé, S. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1085 · Cited by 345
Caceres, J. A., & Goldstein, J. N. (2012) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2012.06.003 · Cited by 328
Robert, S., Chatelain, C., Douxfils, J., Mullier, F., Chatelain, B., & Dogné, J.-M. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0804 · Cited by 325
Zhou, W., Schwarting, S., Illanes, S., Liesz, A., Middelhoff, M., Zorn, M., Bendszus, M., Heiland, S., van Ryn, J., & Veltkamp, R. (2011) · Stroke · doi:10.1161/strokeaha.111.624650 · Cited by 324
Glund, S., Stangier, J., Schmohl, M., Gansser, D., Norris, S., van Ryn, J., Lang, B., Ramael, S., Moschetti, V., Gruenenfelder, F., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60732-2 · Cited by 319
Self-citationPernod, G., Albaladejo, P., Godier, A., Samama, C. M., Susen, S., Gruel, Y., Blais, N., Fontana, P., Cohen, A., Llau, J. V., et al. (2013) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2013.04.009 · Cited by 309
Fauchier, L., Hylek, E., Knight, E., Lane, D., Levi, M., Marin, F., Palareti, G., Collet, J.-P., Rubboli, A., Poli, D., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-10-0690 · Cited by 280
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Majeed, A., Hwang, H.-G., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Wallentin, L., Brueckmann, M., Fraessdorf, M., Yusuf, S., & Schulman, S. (2013) · Circulation · doi:10.1161/circulationaha.113.002332 · Cited by 277
Macle, L., Cairns, J., Leblanc, K., Tsang, T., Skanes, A., Cox, J. L., Healey, J. S., Bell, A., Pilote, L., Andrade, J. G., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.591 · Cited by 272
Lee, C. J., & Ansell, J. E. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03916.x · Cited by 272
Furie, K. L., Goldstein, L. B., Albers, G. W., Khatri, P., Neyens, R., Turakhia, M. P., Turan, T. N., & Wood, K. A. (2012) · Stroke · doi:10.1161/str.0b013e318266722a · Cited by 270
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
Baghaei, F., Blixter, I. F., Gustafsson, K., Stigendal, L., Sten-Linder, M., Strandberg, K., Hillarp, A., Lindahl, T., & and from the expert group on coagulation of the External Quality Assurance in Laboratory Medicine in Sweden (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-06-0342 · Cited by 269
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
Stangier, J., & Feuring, M. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32834f1b0c · Cited by 265
Self-citationAnticoagulation Drug Therapy: A Review
Harter, K., Levine, M., & Henderson, S. (2015) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2014.12.22933 · Cited by 257
Baglin, T., Hillarp, A., Tripodi, A., Elalamy, I., Buller, H., & Ageno, W. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12149 · Cited by 256
Management of acute stroke in patients taking novel oral anticoagulants
Hankey, G. J., Norrving, B., Hacke, W., & Steiner, T. (2014) · International Journal of Stroke · doi:10.1111/ijs.12295 · Cited by 63
Metadata
- Authors
- Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2010
- Volume
- 103
- Issue
- 06
- Pages
- 1116-1127
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2113446992
- Cited by
- 1,382
- References
- 31
- FWCI
- 151.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.